Johnson & Johnson (NYSE:JNJ) Medical Device Companies said today it is partnering with the Medical University of South Carolina to implement an evidence-based infection prevention system using JJMDC’s surgical products.
Through the deal, the groups look to reduce healthcare-associated infections, which are a leading cost of death in acute care hospitals and cost the healthcare systems billions, J&J said. Central line-associated bloodstream infections and SSIs are “among the costliest healthcare-associated infections,” according to the company, accounting for more than half of the total annual cost for HAIs.
“Healthcare-associated infections are a very real concern that can have significant ramifications for everyone involved. We are committed to being a leader in infection risk reduction efforts and have engaged the Johnson & Johnson Medical Devices Companies to help us reduce infection risk in our surgical facilities. Through its evidence-based approach, JJMDC is helping us to identify and address our needs specific to infection risk management, including appropriate techniques for its products, and provide training and education resources for our care team members. Our common goal is providing the highest level of patient care possible,” Dr. Danielle Scheurer of the Medical University of South Carolina said in a preapred statement.
The partnership will utilize JJMDC’s CareAdvantage program designed to address risk of infection through a data-driven approach to address risk factors of costly infections and reduce variation in clinical practices and purchasing patterns, the company said. The program includes evidence-based practices to address risk factors for both BSIs and SSIs using JJMDC portfolio equipment.
“Infection risk management has never been more important to helping hospitals meet the Triple Aim goal of reducing cost, improving outcomes and increasing patient satisfaction. Healthcare-associated infections can create significant financial and operational challenges for provider organizations. Based on careful evaluation of evidence, our approach focuses on effective, efficient patient care delivery and fits naturally as a priority in successful value-based care practices,” JJMDC health economics & market access VP Dr. Christina Farup said in a press release.
